DaVita Clinical Research has formed a pact with Pyxant Labs where Pyxant will provide bioanalytical laboratory services for DCR's early-phase clinical trials.
“The combination of clinical study conduct in close coordination (and proximity) with bioanalytical services is advantageous to our mutual customers and, frankly, usually superior to larger organizations which offer turnkey services,” Pyxant President and CEO Maurice Gaubatz told Outsourcing-Pharma.com.
Pyxant Labs is a contract research laboratory specializing in bioanalytical chemistry support for pharma clients. Through this collaboration, Pyxant will provide bioanalytical method development, sample analysis and formulation development for early clinical trials conducted at DCR's clinical research units.
“Almost all sites offering both clinical conduct and bioanalytical services at the same site originally established their expertise within one area or the other, and not both from Day One,” Gaubatz told us. “Building bioanalytical services from a basis of clinical operations experience, for example, demands fundamentally different competencies.”
In a recent interview with DaVita, the company said there is an increasing demand for innovative and adaptive clinical trials among big pharmaceutical clients. The company previously expanded into renal trials.
Gaubatz added that there have been multiple examples during the last 10 years “when one department (say bioanalytical) crashed a company which offered otherwise excellent services (say clinical).”
“Building a single organization with such different competencies is more difficult to get right than specialization, both for technological capabilities and operations efficiency,” Gaubatz added. “So, you don’t really see integrated CROs which offer the very best within each practice area, compared to using multiple specialists.”
DCR has built “the best clinical research site that I have toured in the last 10 years,” he noted. “Their operations team at the site, corporate culture and high ethical approach made a compelling case for our association.”